Search
for
Sort by
Research 151–180 of 777
- Review of Promising Off-Label Use of Deucravacitinib
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
- Baricitinib as a treatment for myasthenia gravis: A case report
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- Poster Presentations
- Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- The Role of Janus Kinase Inhibitors in Dermatology
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Turning JAK STATic, a peek into the future of dermatology therapeutics
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Ritlecitinib: First Approval
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review